{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-011219","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.645073+00:00","generated_at":"2026-06-04T19:31:41.744913+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Intensity Therapeutics FY 2023 net loss $10.5M; cash $14.8M funds ops through Q1 2025","bullets":["Net loss $10.5M in 2023 vs $7.6M in 2022; includes $2.3M non-cash loss on debt conversion.","Year-end cash & investments $14.8M; company expects runway to end of Q1 2025.","R&D expenses $4.8M (vs $5.1M); G&A $3.5M (vs $2.4M) due to public-company costs.","Phase 3 sarcoma trial (INVINCIBLE-3) targeting 333 patients, overall survival endpoint; enrollment starts mid-2024.","Phase 2/3 breast cancer program (INVINCIBLE-4) to begin mid-2024; endpoint pathological complete response rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-011219","json":"https://secwatch.observer/filing/0001628280-24-011219.json","markdown":"https://secwatch.observer/filing/0001628280-24-011219.md","text":"https://secwatch.observer/filing/0001628280-24-011219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/0001628280-24-011219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/intensity-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:31:41.744913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f4b89fe195f695dce51757d2d4a622bd19722db","claim":"INTENSITY THERAPEUTICS, INC. reported financial results for year ended December 31, 2023.","evidence_excerpt":"On March 14, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/0001628280-24-011219-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}